Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma ScienceNSE:STAR +2.45%68 Graham Number is ₹512.74 as of Mar. 2026, which is 100% below its 10-year median of 1.83. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹782.71 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 604 Drug Manufacturers companies, Strides Pharma Science ranks worse than 65.4% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
The historical rank and industry rank for Strides Pharma Science's Graham Number or its related term are showing as below:
NSE:STAR'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.51 Med: 1.83 Max: 6.29
Current: 2.1
During the past 13 years, the highest Price to Graham Number ratio of Strides Pharma Science was 6.29. The lowest was 0.51. And the median was 1.83.
NSE:STAR's Price-to-Graham-Number is ranked worse than 65.4% of 604
companies
in the Drug Manufacturers industry
Industry Median: 1.53
vs NSE:STAR: 2.10
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Strides Pharma Science (NSE:STAR) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Strides Pharma Science's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
1074.90
/
512.74
=
2.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Strides Pharma Science Graham Number Related Terms
Strides Pharma Science Graham Number Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Graham Number of ₹512.74 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Strides Pharma Science and its competitors. This is 27919% above median its historical median of 1.83. Over the past decade, Strides Pharma Science's Graham Number has ranged from 0.51 to 6.29. According to the industry distribution chart, Strides Pharma Science ranks #395 out of 604 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Strides Pharma Science's Graham Number too high?
Strides Pharma Science's current Graham Number of ₹512.74 is 27919% above median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 6.29. Based on the distribution chart, Strides Pharma Science ranks #395 out of 604 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Graham Number compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #395 out of 604 companies for Graham Number. This places Strides Pharma Science in the lower half of its industry. The industry median Graham Number is 1.53. Historically, Strides Pharma Science's own Graham Number has ranged from 0.51 to 6.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.53, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Graham Number is ₹512.74, which is 27919% above median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹782.71, compared to a current price of ₹1,074.90 — trading 37.3% above its estimated fair value. The current Graham Number is ₹512.74, which is 27919% above median its 10-year median of 1.83. Strides Pharma Science's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Graham Number is ₹512.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,074.90 is trading 37.3% above its estimated GF Value™ of ₹782.71.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Graham Number: ₹512.74 (27919% above median its 10-year median of 1.83)
GF Value™: ₹782.71 vs. price of ₹1,074.90 (37.3% above fair value)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score
Get the complete analysis for NSE:STAR
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
